Hyderabad's Bharat Biotech partners with GSK to lead development of Shigella vaccine
The agreement marks a critical step in the advancement of this promising vaccine, targeting Shigellosis—a severe form of bacterial diarrhoea that disproportionately affects children under five in low- and middle-income countries.